Suchergebnisse - "Chu, Tianqing"

PubPharm (154)

1

Association of metabolomics with PD-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancer

enthalten in: Journal for immunotherapy of cancer | 2024

von Zheng, L. | Hu, F. | Huang, L. | +14

2

EGFR and ERBB2 Exon 20 Insertion Mutations in Chinese Non-small Cell Lung Cancer Patients : Pathological and Molecular Characterization, and First-Line Systemic Treatment Evaluation

enthalten in: Targeted oncology | 2024

von Zhao, R. | Li, J. | Guo, L. | +9

3

EGFR and ERBB2 Exon 20 Insertion Mutations in Chinese Non-small Cell Lung Cancer Patients: Pathological and Molecular Characterization, and First-Line Systemic Treatment Evaluation

enthalten in: Targeted oncology | 2024

von Zhao, R. | Li, J. | Guo, L. | +9

4

Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer

enthalten in: Thoracic cancer | 2024

von Lin, G. | Wang, Z. | Chu, Q. | +98

5

Anti-angiogenic therapy or immunotherapy? A real-world study of patients with advanced non-small cell lung cancer with EGFR/HER2 exon 20 insertion mutations

enthalten in: Frontiers in oncology | 2024

von Li, J. | Xie, M. | Zhao, R. | +8

6

Rechallenge of immune checkpoint inhibitors in advanced non‐small cell lung cancer

enthalten in: Thoracic Cancer | 2024

von Lin, G. | Wang, Z. | Chu, Q. | +103

7

Efficacy of alectinib in lung adenocarcinoma patients with different anaplastic lymphoma kinase (ALK) rearrangements and co-existing alterations-a retrospective cohort study

enthalten in: Translational lung cancer research | 2023

von Li, J. | Huang, K. | Ji, H. | +9

8

Clinical definition of secondary resistance to immunotherapy in non-small cell lung cancer

enthalten in: Thoracic cancer | 2023

von Huang, D. | Lin, G. | Chu, Q. | +98

9

Single-cell RNA-sequencing uncovers the dynamic changes of tumour immune microenvironment in advanced lung adenocarcinoma

enthalten in: BMJ open respiratory research | 2023

von Lu, H. | Qian, J. | Cheng, L. | +3

10

Rationale and design of a multicenter, randomized phase II trial of durvalumab with or without multitarget tyrosine kinase inhibitor as maintenance treatment in extensive-stage small-cell lung cancer patients (DURABLE study)

enthalten in: The clinical respiratory journal | 2023

von Zhang, B. | Zhong, H. | Shi, C. | +10

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[16]